Cytiva set to invest $200m in APAC

Global life sciences company Cytiva will invest some $200 million in the Asia-Pacific region to expand production, establish world-class facilities and foster local talent to better serve customers in China and elsewhere.

The exercise is part of a $1.5 billion investment plan of Cytiva, a former biopharmaceutical arm under conglomerate GE. The goal is to consolidate foothold and enhance supply chain reliance for the fast-developing industry.

A core pillar of the strategy includes tripling the capacity of bioprocessing single-use consumables in China, the company's Asia-Pacific headquarters and the second-largest single-country market after the United States.